Good observation. GSS announced FDA approval on 4 June. Today is exactly six months since that announcement.
GSS had long trumpeted putting in place an on-the-ground US based marketing team in anticipation of such approval, so that they would then immediately be able to generate sales once approval had been received. The salaries of the US marketing team are very expensive and all the more so when they do not bring in the revenue they have promised.
Despite the effusiveness of GSS prior to and after receiving FDA approval, and detailed descriptions of the alleged large and enthusiastic pipeline of potential customers, there has not yet been one single product sale.
It is far too late already to say the clock is ticking. The US marketing team should be held accountable for their performance or lack thereof and what they report back to head office. Even if they announce a first sale tomorrow, it is too little too late. The new CEO should demand accountability from the US based marketing team. She should also be cautious about repeating their unvalidated enthusiastic statements, which appear to be based more upon self-preservation than truthfulness.
GSS Price at posting:
65.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)